Solid Tumor Testing Market in the US 2018-2022
About Solid Tumor Testing
Solid tumor testing is a medical procedure that helps in the early detection of cancer. It is done to avoid the spread of cancerous cells throughout the body and allow for effective treatment.
Technavio’s analysts forecast the solid tumor testing market in the US to grow at a CAGR of 10.72% during the period 2018-2022.
Covered in this report
The report covers the present scenario and the growth prospects of the solid tumor testing market in the US for 2018-2022. To calculate the market size, the report presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources.Technavio's report, Solid Tumor Testing Market in the US 2018-2022, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.
Technavio Announces the Publication of its Research Report – Solid Tumor Testing Market in the US 2018-2022
Technavio recognizes the following companies as the key players in the solid tumor testing market in the US: Agilent Technologies, Becton, Dickinson and Company, Danaher, F. Hoffmann-La Roche, Illumina, and Thermo Fisher Scientific.
Commenting on the report, an analyst from Technavio’s team said: “One trend in the market is adoption of NGS in cancer diagnostics. The growing adoption of NGS in cancer diagnostics is identified to be one of the key trends driving the growth of the solid tumor testing market in the US. Next-generation sequencing (NGS) is a high-throughput methodology that enables rapid sequencing of the base pairs in DNA or RNA samples.”
According to the report, one driver in the market is growing prevalence of cancer. Globally, cancer is the primary cause for the high mortality rates among all age groups. In 2014, 1.6 million new cancer cases were diagnosed out of which 600,000 individuals succumbed to the disease. Many types of cancer are curable if diagnosed at early stage, however, few are fatal.
Further, the report states that one challenge in the market is high cost of sequencing. As sequencing involves the handling of high throughput data, the maintenance of precision and accuracy requires highly skilled personnel and cutting-edge technology and equipment. Thus, setting up a laboratory consumes a significant amount of capital.
Becton, Dickinson and Company
F. Hoffmann-La Roche
Thermo Fisher Scientific